Study of MicroRNA Levels in Adults with Septic Shock or Critical Illness in ICU

What this Trial Is About

Sepsis-induced immunosuppression SIS is a frequent complication in patients experiencing septic shock. This condition is marked by reduced expression of Human leukocyte antigen isotype DR HLA-DR on circulating monocytes, which is linked to a higher risk of secondary infections and death. The miRSep study aims to better understand how early microRNA miRNA changes affect HLA-DR expression in these patients with septic shock. The study is observational and involves two groups patients in the ICU diagnosed with septic shock and critically ill ICU patients without sepsis. Participants will be observed to compare miRNA expression patterns between those with or without sepsis-induced immunosuppression. The primary outcome is measured three days after ICU admission, focusing on differences in miRNA expression. Secondary outcomes include the relationship between miRNA levels and sepsis outcomes, such as 30-day mortality. Participants will be adults admitted to the ICU and expected to stay more than 48 hours. Researchers will collect data within the first few days of ICU admission, including laboratory assessments related to miRNA and immune markers. The study tracks outcomes for up to 30 days following admission to better understand the role of miRNA in septic shock. Participation involves monitoring and data collection without interventional treatments, and the study is expected to complete by the end of 2027.

MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK